JP2014513068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513068A5 JP2014513068A5 JP2014502848A JP2014502848A JP2014513068A5 JP 2014513068 A5 JP2014513068 A5 JP 2014513068A5 JP 2014502848 A JP2014502848 A JP 2014502848A JP 2014502848 A JP2014502848 A JP 2014502848A JP 2014513068 A5 JP2014513068 A5 JP 2014513068A5
- Authority
- JP
- Japan
- Prior art keywords
- folr1
- sample
- antibody
- cancer
- score
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100035139 Folate receptor alpha Human genes 0.000 claims description 141
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims description 141
- 238000000034 method Methods 0.000 claims description 98
- 238000010186 staining Methods 0.000 claims description 87
- 206010028980 Neoplasm Diseases 0.000 claims description 86
- 239000000523 sample Substances 0.000 claims description 68
- 201000011510 cancer Diseases 0.000 claims description 57
- 238000001514 detection method Methods 0.000 claims description 44
- 238000003364 immunohistochemistry Methods 0.000 claims description 43
- 239000013074 reference sample Substances 0.000 claims description 39
- 210000001519 tissue Anatomy 0.000 claims description 25
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 15
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 15
- 101710112752 Cytotoxin Proteins 0.000 claims description 14
- 206010033128 Ovarian cancer Diseases 0.000 claims description 14
- 239000012472 biological sample Substances 0.000 claims description 14
- 239000002619 cytotoxin Substances 0.000 claims description 14
- 208000020816 lung neoplasm Diseases 0.000 claims description 14
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 229940127121 immunoconjugate Drugs 0.000 claims description 12
- 239000008188 pellet Substances 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 10
- FUHCFUVCWLZEDQ-UHFFFAOYSA-N 1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid Chemical compound O=C1CCC(=O)N1OC(=O)C(S(=O)(=O)O)CCSSC1=CC=CC=N1 FUHCFUVCWLZEDQ-UHFFFAOYSA-N 0.000 claims description 8
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 claims description 6
- NNPUPCNWEHWRPW-UHFFFAOYSA-N 4-(pyridin-2-yldisulfanyl)-2-sulfobutanoic acid Chemical compound OC(=O)C(S(O)(=O)=O)CCSSC1=CC=CC=N1 NNPUPCNWEHWRPW-UHFFFAOYSA-N 0.000 claims description 6
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims description 6
- 229960002685 biotin Drugs 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 claims description 6
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 claims description 6
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 6
- -1 maleimidomethyl Chemical group 0.000 claims description 6
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 claims description 6
- 230000002285 radioactive effect Effects 0.000 claims description 6
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 229910052722 tritium Inorganic materials 0.000 claims description 6
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 claims description 5
- UQVNRKBFAXNOGA-LWTNMJDUSA-N (E)-tomaymycin Chemical class CO[C@H]1NC2=CC(O)=C(OC)C=C2C(=O)N2C\C(=C\C)C[C@@H]12 UQVNRKBFAXNOGA-LWTNMJDUSA-N 0.000 claims description 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 3
- ORKSBKSSOSUJOY-UHFFFAOYSA-N 2,5-dioxo-1-[4-(pyridin-2-yldisulfanyl)pentanoyloxy]pyrrolidine-3-sulfonic acid Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CC(S(O)(=O)=O)C1=O ORKSBKSSOSUJOY-UHFFFAOYSA-N 0.000 claims description 3
- OWDQCSBZQVISPN-UHFFFAOYSA-N 2-[(2,5-dioxopyrrolidin-1-yl)amino]-4-(2-iodoacetyl)benzoic acid Chemical compound OC(=O)C1=CC=C(C(=O)CI)C=C1NN1C(=O)CCC1=O OWDQCSBZQVISPN-UHFFFAOYSA-N 0.000 claims description 3
- JNWSNQJRTXEHIV-UHFFFAOYSA-N 4-(pyridin-2-yldisulfanyl)-2-sulfopentanoic acid Chemical compound OC(=O)C(S(O)(=O)=O)CC(C)SSC1=CC=CC=N1 JNWSNQJRTXEHIV-UHFFFAOYSA-N 0.000 claims description 3
- 240000006409 Acacia auriculiformis Species 0.000 claims description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- 229940049706 benzodiazepine Drugs 0.000 claims description 3
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims description 3
- 229930195731 calicheamicin Natural products 0.000 claims description 3
- 229930188854 dolastatin Natural products 0.000 claims description 3
- 229960005501 duocarmycin Drugs 0.000 claims description 3
- 229930184221 duocarmycin Natural products 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 3
- YACHGFWEQXFSBS-RJXCBBHPSA-N leptomycin Chemical class OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)\C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-RJXCBBHPSA-N 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 239000012188 paraffin wax Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 claims description 3
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 claims description 2
- 230000003432 anti-folate effect Effects 0.000 claims description 2
- 229940127074 antifolate Drugs 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 239000004052 folic acid antagonist Substances 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 210000004923 pancreatic tissue Anatomy 0.000 claims description 2
- 210000003079 salivary gland Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 30
- 102000050083 Class E Scavenger Receptors Human genes 0.000 claims 8
- 108091005418 scavenger receptor class E Proteins 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 208000023965 endometrium neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 201000004228 ovarian endometrial cancer Diseases 0.000 claims 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
- 229940080818 propionamide Drugs 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 47
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 13
- 201000005202 lung cancer Diseases 0.000 description 13
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- ZOHXWSHGANNQGO-DSIKUUPMSA-N 1-amino-4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]-1-oxobutane-2-sulfonic acid Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(N)=O)S(O)(=O)=O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ZOHXWSHGANNQGO-DSIKUUPMSA-N 0.000 description 2
- 102000010451 Folate receptor alpha Human genes 0.000 description 2
- 108050001931 Folate receptor alpha Proteins 0.000 description 2
- 241000920340 Pion Species 0.000 description 2
- LJFFDOBFKICLHN-IXWHRVGISA-N [(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[methyl(4-sulfanylpentanoyl)amino]propanoate Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)S)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 LJFFDOBFKICLHN-IXWHRVGISA-N 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 101150095463 Folr1 gene Proteins 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161471007P | 2011-04-01 | 2011-04-01 | |
| US61/471,007 | 2011-04-01 | ||
| PCT/US2012/031544 WO2012135675A2 (en) | 2011-04-01 | 2012-03-30 | Methods for increasing efficacy of folr1 cancer therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016093915A Division JP2016147901A (ja) | 2011-04-01 | 2016-05-09 | Ｆｏｌｒ１がん治療の有効性を増加させるための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513068A JP2014513068A (ja) | 2014-05-29 |
| JP2014513068A5 true JP2014513068A5 (cg-RX-API-DMAC7.html) | 2015-05-14 |
| JP6018621B2 JP6018621B2 (ja) | 2016-11-02 |
Family
ID=46932392
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014502848A Active JP6018621B2 (ja) | 2011-04-01 | 2012-03-30 | Ｆｏｌｒ１がん治療の有効性を増加させるための方法 |
| JP2016093915A Pending JP2016147901A (ja) | 2011-04-01 | 2016-05-09 | Ｆｏｌｒ１がん治療の有効性を増加させるための方法 |
| JP2018071500A Pending JP2018118997A (ja) | 2011-04-01 | 2018-04-03 | Ｆｏｌｒ１がん治療の有効性を増加させるための方法 |
| JP2019144277A Pending JP2019194257A (ja) | 2011-04-01 | 2019-08-06 | Ｆｏｌｒ１がん治療の有効性を増加させるための方法 |
| JP2020163354A Pending JP2021006547A (ja) | 2011-04-01 | 2020-09-29 | Ｆｏｌｒ１がん治療の有効性を増加させるための方法 |
| JP2022019315A Withdrawn JP2022062219A (ja) | 2011-04-01 | 2022-02-10 | Ｆｏｌｒ１がん治療の有効性を増加させるための方法 |
| JP2024065419A Pending JP2024099612A (ja) | 2011-04-01 | 2024-04-15 | Ｆｏｌｒ１がん治療の有効性を増加させるための方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016093915A Pending JP2016147901A (ja) | 2011-04-01 | 2016-05-09 | Ｆｏｌｒ１がん治療の有効性を増加させるための方法 |
| JP2018071500A Pending JP2018118997A (ja) | 2011-04-01 | 2018-04-03 | Ｆｏｌｒ１がん治療の有効性を増加させるための方法 |
| JP2019144277A Pending JP2019194257A (ja) | 2011-04-01 | 2019-08-06 | Ｆｏｌｒ１がん治療の有効性を増加させるための方法 |
| JP2020163354A Pending JP2021006547A (ja) | 2011-04-01 | 2020-09-29 | Ｆｏｌｒ１がん治療の有効性を増加させるための方法 |
| JP2022019315A Withdrawn JP2022062219A (ja) | 2011-04-01 | 2022-02-10 | Ｆｏｌｒ１がん治療の有効性を増加させるための方法 |
| JP2024065419A Pending JP2024099612A (ja) | 2011-04-01 | 2024-04-15 | Ｆｏｌｒ１がん治療の有効性を増加させるための方法 |
Country Status (30)
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110166319A1 (en) * | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
| EP2399609B1 (en) | 2005-08-24 | 2015-03-18 | ImmunoGen, Inc. | Process for preparing maytansinoid antibody conjugates |
| IL300840A (en) | 2009-06-03 | 2023-04-01 | Immunogen Inc | coupling methods |
| CN103037900B (zh) | 2010-02-24 | 2016-04-06 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| SI2691155T1 (sl) | 2011-03-29 | 2019-03-29 | Immunogen, Inc. | Priprava majtanzinoidnih konjugatov protiteles v postopku z enim korakom |
| CA2831426C (en) * | 2011-04-01 | 2023-02-21 | Immunogen, Inc. | Methods for increasing efficacy of folr1 cancer therapy |
| CN104755498B (zh) | 2012-08-31 | 2019-06-18 | 伊缪诺金公司 | 用于检测叶酸受体1的诊断测定和试剂盒 |
| MX359599B (es) | 2012-10-04 | 2018-09-12 | Immunogen Inc | Uso de una membrana de pvdf para purificar conjugados de agentes de unión celular y agentes citotóxicos. |
| US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
| TWI614266B (zh) * | 2012-12-07 | 2018-02-11 | Kyowa Hakko Kirin Co Ltd | 抗ｆｏｌｒ１抗體 |
| BR112015014712A2 (pt) | 2012-12-21 | 2017-07-11 | Abgenomics Int Inc | ligadores de autoimolação hidrofílicos e seus conjugados |
| US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| KR20240068778A (ko) * | 2013-05-14 | 2024-05-17 | 이뮤노젠 아이엔씨 | 항-folr1 면역접합체 투약 섭생 |
| US9637547B2 (en) * | 2013-08-30 | 2017-05-02 | Immunogen, Inc. | Monoclonal antibodies for detection of folate receptor 1 |
| SG10202102555TA (en) * | 2013-10-08 | 2021-04-29 | Immunogen Inc | Anti-folr1 immunoconjugate dosing regimens |
| US20150297744A1 (en) * | 2014-03-28 | 2015-10-22 | Immunogen, Inc. | Anti-FOLR1 Immunoconjugate Dosing Regimens |
| AU2015276821A1 (en) * | 2014-06-20 | 2017-01-12 | Abgenomics International Inc. | Anti-folate receptor aplha (FRA) antibody-drug conjugates and methods of using thereof |
| CN109147874A (zh) | 2014-09-02 | 2019-01-04 | 伊缪诺金公司 | 用于配制抗体药物缀合物组合物的方法 |
| KR20240023671A (ko) | 2014-09-03 | 2024-02-22 | 이뮤노젠 아이엔씨 | 세포독성 벤조다이아제핀 유도체 |
| TW201613930A (en) | 2014-09-03 | 2016-04-16 | Immunogen Inc | Cytotoxic benzodiazepine derivatives |
| HRP20201928T1 (hr) | 2014-11-20 | 2021-02-05 | F. Hoffmann - La Roche Ag | Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1 |
| MX2017006571A (es) | 2014-11-20 | 2017-09-29 | Hoffmann La Roche | Moleculas de union a antigeno biespecificas activadoras de celulas t. |
| LT3221357T (lt) | 2014-11-20 | 2020-08-25 | F. Hoffmann-La Roche Ag | Bendros lengvosios grandinės ir naudojimo būdai |
| AU2016298439B2 (en) * | 2015-07-30 | 2018-11-08 | Expression Pathology, Inc. | Quantifying FR-alpha and GART proteins for optimal cancer therapy |
| IL257531B2 (en) | 2015-09-17 | 2023-04-01 | Immunogen Inc | Medicinal compositions containing anti-folr1 immunoconjugates |
| DK3380525T3 (da) | 2015-11-25 | 2024-01-29 | Immunogen Inc | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf |
| IL260289B (en) | 2016-01-08 | 2022-08-01 | Bioalliance Cv | Tetravalent anti-psgl-1 antibodies and uses thereof |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| EP3518943A4 (en) | 2016-09-28 | 2020-04-22 | Atossa Therapeutics, Inc. | METHOD FOR ADAPTIVE CELL THERAPY |
| CN116785450A (zh) | 2017-02-28 | 2023-09-22 | 伊缪诺金公司 | 具有自分解肽接头的类美登素衍生物和其缀合物 |
| WO2018195243A1 (en) | 2017-04-20 | 2018-10-25 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
| IT201700087291A1 (it) * | 2017-07-28 | 2019-01-28 | Fondazione St Italiano Tecnologia | Metodo di imaging di un campione biologico e relativa sonda |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| EP3732178A1 (en) | 2017-12-28 | 2020-11-04 | ImmunoGen, Inc. | Benzodiazepine derivatives |
| MX2020009522A (es) * | 2018-03-13 | 2020-10-22 | Phanes Therapeutics Inc | Anticuerpos anti-folato del receptor 1 y usos de los mismos. |
| AU2020240310A1 (en) | 2019-03-21 | 2021-10-07 | Immunogen, Inc. | Methods of preparing cell-binding agent-drug conjugates |
| EP3947395A1 (en) | 2019-03-29 | 2022-02-09 | ImmunoGen, Inc. | Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases |
| EP3958977B1 (en) | 2019-04-26 | 2023-09-13 | ImmunoGen, Inc. | Camptothecin derivatives |
| CA3138272A1 (en) | 2019-04-29 | 2020-11-05 | Immunogen, Inc. | Biparatopic fr-alpha antibodies and immunoconjugates |
| JP2022534808A (ja) * | 2019-06-06 | 2022-08-03 | ミシック セラピューティクス インコーポレイテッド | 抗原結合タンパク質構築物およびその使用 |
| CN111579798A (zh) * | 2020-05-29 | 2020-08-25 | 深圳市锦欣医疗科技创新中心有限公司 | 一种评估子宫内膜容受性的试剂盒及其使用方法 |
| TW202306995A (zh) * | 2021-06-04 | 2023-02-16 | 美商免疫遺傳股份有限公司 | 治療具有可溶性ＦＲ－α之患者之癌症 |
| US20250177550A1 (en) * | 2022-03-11 | 2025-06-05 | Astrazeneca Ab | A scoring method for an anti-fr alpha antibody drug conjugate therapy |
| WO2025094146A1 (en) | 2023-11-02 | 2025-05-08 | Immunogen Switzerland Gmbh | Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates |
| US12258396B1 (en) * | 2024-02-02 | 2025-03-25 | Medicovestor, Inc. | Methods of using immunotherapeutics that bind folate receptor alpha |
| CN117741149A (zh) * | 2024-02-19 | 2024-03-22 | 卡秋(江苏)生物科技有限公司 | 一种用于卵巢癌细胞叶酸受体α的检测试剂盒及其应用 |
| WO2025195447A1 (zh) * | 2024-03-22 | 2025-09-25 | 北京桦冠生物技术有限公司 | 结合folr1蛋白的抗体、抗体药物偶联物及其用途 |
Family Cites Families (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4563304A (en) | 1981-02-27 | 1986-01-07 | Pharmacia Fine Chemicals Ab | Pyridine compounds modifying proteins, polypeptides or polysaccharides |
| US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US20040049014A1 (en) | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| JPH049249A (ja) | 1990-04-27 | 1992-01-14 | Kusuda:Kk | 塗型剤吹き付け機 |
| US6916605B1 (en) | 1990-07-10 | 2005-07-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| DE69332948T2 (de) | 1992-03-05 | 2003-11-27 | Board Of Regents, The University Of Texas System | Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US20030148406A1 (en) | 1992-03-17 | 2003-08-07 | David John King | Multivalent antigen-binding proteins |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| WO1997011971A1 (en) | 1995-09-28 | 1997-04-03 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
| US6596850B1 (en) | 1998-01-30 | 2003-07-22 | Ixsys, Incorporated | Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same |
| CA2354862A1 (en) | 1998-10-19 | 2000-04-27 | Yeda Research And Development Co. Ltd. | Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
| US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
| IT1307309B1 (it) | 1999-12-30 | 2001-10-30 | Enea Ente Nuove Tec | Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono. |
| CN102805868A (zh) | 2000-03-31 | 2012-12-05 | 普渡研究基金会 | 用配体-免疫原缀合物治疗的方法 |
| DE10037759A1 (de) | 2000-08-03 | 2002-07-04 | Gruenenthal Gmbh | Screeningverfahren |
| ATE400030T1 (de) | 2001-02-19 | 2008-07-15 | Merck Patent Gmbh | Methode zur identifizierung von t-zellepitopen und deren anwendung zur herstellung von molekülen mit reduzierter immunogenität |
| US20030087250A1 (en) | 2001-03-14 | 2003-05-08 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
| RU2316349C2 (ru) | 2001-05-02 | 2008-02-10 | Пердью Рисерч Фаундейшн | Лечение и диагностика заболеваний, опосредованных макрофагами |
| US7314974B2 (en) | 2002-02-21 | 2008-01-01 | Monsanto Technology, Llc | Expression of microbial proteins in plants for production of plants with improved properties |
| WO2003074704A1 (fr) | 2002-03-01 | 2003-09-12 | Japan Envirochemicals, Ltd. | Proteines capables de se lier aux hormones sexuelles feminines et procede de preparation |
| CA2482607C (en) | 2002-04-22 | 2013-06-11 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi |
| WO2004043989A2 (en) | 2002-11-07 | 2004-05-27 | Medarex, Inc. | Human monoclonal antibodies to heparanase |
| EP1481993A1 (en) | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
| US20050255114A1 (en) | 2003-04-07 | 2005-11-17 | Nuvelo, Inc. | Methods and diagnosis for the treatment of preeclampsia |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| JP5416338B2 (ja) | 2003-05-09 | 2014-02-12 | デューク ユニバーシティ | Ｃｄ２０特異的抗体およびその使用方法 |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| KR101424624B1 (ko) | 2003-05-14 | 2014-07-31 | 이뮤노젠 아이엔씨 | 약물 콘쥬게이트 조성물 |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| ZA200510282B (en) | 2003-07-02 | 2007-03-28 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
| CA2548942C (en) | 2003-12-05 | 2013-10-15 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Anti-sars monoclonal antibodies |
| US20050232919A1 (en) | 2004-02-12 | 2005-10-20 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| WO2005103716A2 (en) | 2004-04-27 | 2005-11-03 | Galapagos N.V. | Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts |
| US7241598B2 (en) | 2004-06-29 | 2007-07-10 | The Chinese University Of Hong Kong | Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering |
| JP5173426B2 (ja) | 2004-10-25 | 2013-04-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗ａｄｄｌ抗体およびこの使用 |
| EP2562259B1 (en) | 2004-12-21 | 2016-07-06 | Monsanto Technology LLC | Transgenic plants with enhanced agronomic traits |
| MX2007008017A (es) | 2004-12-31 | 2007-09-12 | Genentech Inc | Polipeptidos que se ligan a br3 y usos de los mismos. |
| US7700738B2 (en) | 2005-01-27 | 2010-04-20 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| US7608413B1 (en) | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
| DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
| JP2008537778A (ja) * | 2005-03-30 | 2008-09-25 | パーデュー・リサーチ・ファウンデーション | 細胞の葉酸ビタミン受容体の定量化による癌予後診断法 |
| JP2009521206A (ja) | 2005-04-22 | 2009-06-04 | モルフォテック、インク． | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
| JP2008539693A (ja) | 2005-05-12 | 2008-11-20 | オンコセラピー・サイエンス株式会社 | 抗ｄｓｃ２抗体のエフェクター機能を用いて細胞を障害する方法 |
| ES2864039T3 (es) | 2005-05-20 | 2021-10-13 | Lonza Biologics Plc | Expresión de alto nivel de un anticuerpo recombinante en una célula huésped de mamífero |
| CA2609731A1 (en) | 2005-05-24 | 2006-11-30 | Avestha Gengraine Technologies Pvt Ltd. | A method for the production of a monoclonal antibody to cd20 for the treatment of b-cell lymphoma |
| WO2007006041A2 (en) | 2005-07-05 | 2007-01-11 | Purdue Research Foundation | Imaging and therapeutic method using monocytes |
| US7521195B1 (en) | 2005-07-21 | 2009-04-21 | Celera Corporation | Lung disease targets and uses thereof |
| EP1937720B1 (en) | 2005-08-18 | 2014-04-09 | Ramot at Tel-Aviv University Ltd. | Single chain antibodies against beta-amyloid peptide |
| US8044179B2 (en) | 2005-09-13 | 2011-10-25 | National Research Council Of Canada | Methods and compositions for modulating tumor cell activity |
| US20070099251A1 (en) | 2005-10-17 | 2007-05-03 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| PT2913343T (pt) | 2005-12-20 | 2018-11-21 | Sbi Biotech Co Ltd | Anticorpo anti-ilt7 |
| WO2007143561A1 (en) | 2006-06-01 | 2007-12-13 | Mayo Foundation For Medical Education And Research | Immunity to folate receptors |
| EP2502628B1 (en) | 2006-06-23 | 2016-12-14 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
| US7910702B2 (en) | 2006-07-28 | 2011-03-22 | The Governors Of The University Of Alberta | Recombinant antibodies to sclerotinia antigens |
| AU2007284651B2 (en) | 2006-08-09 | 2014-03-20 | Institute For Systems Biology | Organ-specific proteins and methods of their use |
| EP1900752A1 (en) * | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
| EP1900533A1 (de) | 2006-09-16 | 2008-03-19 | J. Zimmer Maschinenbau Gesellschaft m.b.H. | Vorrichtung zum Auftragen von Substanz auf flächige Substrate |
| JP5687822B2 (ja) | 2006-10-12 | 2015-03-25 | 中外製薬株式会社 | 抗ｅｒｅｇ抗体を用いる癌の診断および治療 |
| CA2672581A1 (en) | 2006-12-14 | 2008-06-19 | Forerunner Pharma Research Co., Ltd. | Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same |
| EP2716657A3 (en) | 2006-12-20 | 2014-10-08 | Mmrglobal, Inc. | Antibodies and methods for making and using them |
| US20080227704A1 (en) | 2006-12-21 | 2008-09-18 | Kamens Joanne S | CXCL13 binding proteins |
| WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
| EP2129402A2 (en) | 2007-02-16 | 2009-12-09 | KTB Tumorforschungsgesellschaft mbH | Receptor and antigen targeted prodrug |
| WO2008145136A1 (en) | 2007-05-30 | 2008-12-04 | Aarhus Universitet | Stat3 inactivation by inhibition of the folate receptor pathway |
| EP3569251A1 (en) | 2007-06-25 | 2019-11-20 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
| WO2009017679A2 (en) | 2007-07-31 | 2009-02-05 | Merck & Co., Inc. | Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders |
| CN101139613B (zh) | 2007-08-01 | 2011-06-08 | 姜荣锡 | 抗肿瘤二元多肽及其应用与制备方法 |
| US20090087849A1 (en) * | 2007-09-06 | 2009-04-02 | Tripath Imaging, Inc. | Nucleic acid-based methods and compositions for the detection of ovarian cancer |
| JP5660900B2 (ja) | 2007-12-21 | 2015-01-28 | ノバルティス アーゲー | 有機化合物 |
| JP5848863B2 (ja) | 2008-01-11 | 2016-01-27 | 国立大学法人 東京大学 | 抗ｃｌｄｎ６抗体 |
| WO2009132081A2 (en) | 2008-04-24 | 2009-10-29 | The Research Foundation Of State University Of New York | Monoclonal antibody-based targeting of folate receptors |
| RU2503687C2 (ru) | 2008-04-30 | 2014-01-10 | Иммьюноджен, Инк. | Сшивающие реагенты и их применение |
| RU2487877C2 (ru) | 2008-04-30 | 2013-07-20 | Иммьюноджен, Инк. | Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры) |
| US8383351B2 (en) | 2008-06-11 | 2013-02-26 | Oxford Brookes University | Antibody to inhibin/ activin β-B subunit |
| PL2349274T3 (pl) | 2008-09-17 | 2025-09-22 | Endocyte, Inc. | Koniugaty antyfolianów wiążące się z receptorem folianów |
| US20100092470A1 (en) | 2008-09-22 | 2010-04-15 | Icb International, Inc. | Antibodies, analogs and uses thereof |
| JP2012509058A (ja) | 2008-11-20 | 2012-04-19 | オンコセラピー・サイエンス株式会社 | 前立腺癌を診断または治療するための方法 |
| CN101440130B (zh) | 2008-11-21 | 2011-07-27 | 中国人民解放军第四军医大学 | 一种抗人IL-13Rα2单克隆抗体的重链和轻链的可变区 |
| CN110470835A (zh) | 2009-03-24 | 2019-11-19 | 生物概念股份有限公司 | 细胞捕获和分析的装置和方法 |
| CN102574915B (zh) * | 2009-08-06 | 2014-10-22 | 伊缪纳斯制药株式会社 | 特异性结合Aβ寡聚体的抗体及其用途 |
| WO2011032296A1 (en) | 2009-09-21 | 2011-03-24 | Mount Sinai Hospital | Methods and compositions for the diagnosis and treatment of thyroid cancer |
| US9175086B2 (en) | 2010-02-10 | 2015-11-03 | Immunogen, Inc. | CD20 antibodies and uses thereof |
| CN103037900B (zh) | 2010-02-24 | 2016-04-06 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| RU2630608C2 (ru) * | 2010-11-05 | 2017-09-11 | Морфотек Инк. | Рецептор фолиевой кислоты альфа в качестве диагностического и прогностического маркера злокачественных опухолей, экспрессирующих рецептор фолиевой кислоты альфа |
| SI2691155T1 (sl) * | 2011-03-29 | 2019-03-29 | Immunogen, Inc. | Priprava majtanzinoidnih konjugatov protiteles v postopku z enim korakom |
| SG193997A1 (en) * | 2011-03-29 | 2013-11-29 | Immunogen Inc | Process for manufacturing conjugates of improved homogeneity |
| MX2013011201A (es) * | 2011-03-29 | 2013-12-16 | Immunogen Inc | Proceso para la elaboracion de conjugados de mejor homogeneidad. |
| CA2831426C (en) * | 2011-04-01 | 2023-02-21 | Immunogen, Inc. | Methods for increasing efficacy of folr1 cancer therapy |
| US20120282282A1 (en) | 2011-04-04 | 2012-11-08 | Immunogen, Inc. | Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates |
| US9156854B2 (en) | 2011-04-18 | 2015-10-13 | Immunogen, Inc. | Maytansinoid derivatives with sulfoxide linker |
| PL2731972T3 (pl) | 2011-07-15 | 2018-06-29 | Eisai R&D Management Co., Ltd. | Przeciwciała skierowane przeciwko receptorowi folianowemu alfa i ich zastosowania |
| CN104755498B (zh) | 2012-08-31 | 2019-06-18 | 伊缪诺金公司 | 用于检测叶酸受体1的诊断测定和试剂盒 |
| US20150306242A1 (en) | 2012-10-04 | 2015-10-29 | Immunogen, Inc. | Process for preparing stable antibody maytansinoid conjugates |
| KR20240068778A (ko) | 2013-05-14 | 2024-05-17 | 이뮤노젠 아이엔씨 | 항-folr1 면역접합체 투약 섭생 |
| US9637547B2 (en) | 2013-08-30 | 2017-05-02 | Immunogen, Inc. | Monoclonal antibodies for detection of folate receptor 1 |
| SG10202102555TA (en) * | 2013-10-08 | 2021-04-29 | Immunogen Inc | Anti-folr1 immunoconjugate dosing regimens |
| US20150297744A1 (en) * | 2014-03-28 | 2015-10-22 | Immunogen, Inc. | Anti-FOLR1 Immunoconjugate Dosing Regimens |
| JP6670288B2 (ja) | 2014-07-01 | 2020-03-18 | エクスプレッション、パソロジー、インコーポレイテッドＥｘｐｒｅｓｓｉｏｎ Ｐａｔｈｏｌｏｇｙ， Ｉｎｃ． | 化学療法標的に対するｓｒｍアッセイ |
| CN109147874A (zh) | 2014-09-02 | 2019-01-04 | 伊缪诺金公司 | 用于配制抗体药物缀合物组合物的方法 |
| IL257531B2 (en) | 2015-09-17 | 2023-04-01 | Immunogen Inc | Medicinal compositions containing anti-folr1 immunoconjugates |
| CN116785450A (zh) | 2017-02-28 | 2023-09-22 | 伊缪诺金公司 | 具有自分解肽接头的类美登素衍生物和其缀合物 |
| EP3625262A4 (en) | 2017-05-16 | 2021-03-03 | ImmunoGen, Inc. | ANTI-FOLR1 IMMUNE CONJUGATES AND ANTI-PD-1 ANTIBODY COMBINATIONS |
-
2012
- 2012-03-30 CA CA2831426A patent/CA2831426C/en active Active
- 2012-03-30 MX MX2013011098A patent/MX340640B/es active IP Right Grant
- 2012-03-30 EA EA201391351A patent/EA028805B1/ru unknown
- 2012-03-30 UA UAA201312203A patent/UA113403C2/uk unknown
- 2012-03-30 IL IL303208A patent/IL303208A/en unknown
- 2012-03-30 EP EP23196667.2A patent/EP4309671A3/en not_active Withdrawn
- 2012-03-30 MY MYPI2017001279A patent/MY186591A/en unknown
- 2012-03-30 KR KR1020217021056A patent/KR102489185B1/ko active Active
- 2012-03-30 EP EP12764885.5A patent/EP2694106B1/en active Active
- 2012-03-30 SM SM20180103T patent/SMT201800103T1/it unknown
- 2012-03-30 JP JP2014502848A patent/JP6018621B2/ja active Active
- 2012-03-30 CN CN201280015187.1A patent/CN103747802B/zh active Active
- 2012-03-30 EP EP19192583.3A patent/EP3636279B1/en active Active
- 2012-03-30 TR TR2018/02659T patent/TR201802659T4/tr unknown
- 2012-03-30 ME MEP-2018-59A patent/ME03025B/me unknown
- 2012-03-30 CN CN202111663548.0A patent/CN114441757A/zh active Pending
- 2012-03-30 MX MX2015009802A patent/MX346555B/es unknown
- 2012-03-30 US US13/435,857 patent/US8709432B2/en active Active
- 2012-03-30 KR KR1020137028854A patent/KR101982317B1/ko active Active
- 2012-03-30 EP EP17206669.8A patent/EP3318273B1/en active Active
- 2012-03-30 LT LTEP12764885.5T patent/LT2694106T/lt unknown
- 2012-03-30 ES ES12764885.5T patent/ES2661466T3/es active Active
- 2012-03-30 KR KR1020207010226A patent/KR20200039843A/ko not_active Ceased
- 2012-03-30 SG SG2013070040A patent/SG193514A1/en unknown
- 2012-03-30 PL PL12764885T patent/PL2694106T3/pl unknown
- 2012-03-30 CA CA3182262A patent/CA3182262A1/en active Pending
- 2012-03-30 CN CN201810367278.0A patent/CN108743965A/zh active Pending
- 2012-03-30 IL IL281714A patent/IL281714B2/en unknown
- 2012-03-30 AU AU2012236219A patent/AU2012236219B2/en active Active
- 2012-03-30 RS RS20180231A patent/RS56916B1/sr unknown
- 2012-03-30 SG SG10201602553VA patent/SG10201602553VA/en unknown
- 2012-03-30 WO PCT/US2012/031544 patent/WO2012135675A2/en not_active Ceased
- 2012-03-30 DK DK12764885.5T patent/DK2694106T3/en active
- 2012-03-30 ES ES19192583T patent/ES2965109T3/es active Active
- 2012-03-30 KR KR1020197014502A patent/KR102101160B1/ko active Active
- 2012-03-30 BR BR112013025415-7A patent/BR112013025415B1/pt active IP Right Grant
- 2012-03-30 SI SI201231241T patent/SI2694106T1/en unknown
- 2012-03-30 HU HUE12764885A patent/HUE036172T2/hu unknown
- 2012-03-30 UA UAA201609144A patent/UA125636C2/uk unknown
- 2012-03-30 MY MYPI2013003422A patent/MY180894A/en unknown
- 2012-03-30 KR KR1020247002873A patent/KR20240017965A/ko not_active Ceased
- 2012-03-30 KR KR1020237001305A patent/KR20230013283A/ko not_active Ceased
- 2012-03-30 PT PT127648855T patent/PT2694106T/pt unknown
- 2012-03-30 EA EA201791843A patent/EA201791843A3/ru unknown
- 2012-03-30 HR HRP20180358TT patent/HRP20180358T1/hr unknown
- 2012-10-26 NO NO12884208A patent/NO2893540T3/no unknown
-
2013
- 2013-09-26 MX MX2019010336A patent/MX2019010336A/es unknown
- 2013-09-29 IL IL228538A patent/IL228538B/en active IP Right Grant
-
2014
- 2014-04-04 US US14/245,797 patent/US20140363453A1/en not_active Abandoned
-
2016
- 2016-05-09 JP JP2016093915A patent/JP2016147901A/ja active Pending
-
2017
- 2017-05-02 AU AU2017202927A patent/AU2017202927B2/en active Active
- 2017-11-09 US US15/807,831 patent/US11135305B2/en active Active
-
2018
- 2018-02-27 CY CY20181100241T patent/CY1119960T1/el unknown
- 2018-04-03 JP JP2018071500A patent/JP2018118997A/ja active Pending
- 2018-11-12 IL IL262956A patent/IL262956B/en active IP Right Grant
-
2019
- 2019-04-15 AU AU2019202611A patent/AU2019202611B2/en active Active
- 2019-08-06 JP JP2019144277A patent/JP2019194257A/ja active Pending
-
2020
- 2020-03-25 IL IL273614A patent/IL273614A/en unknown
- 2020-09-29 JP JP2020163354A patent/JP2021006547A/ja active Pending
- 2020-11-30 ZA ZA2020/07440A patent/ZA202007440B/en unknown
-
2021
- 2021-07-21 AU AU2021206842A patent/AU2021206842B2/en active Active
- 2021-08-31 US US17/463,156 patent/US20220143208A1/en not_active Abandoned
-
2022
- 2022-02-10 JP JP2022019315A patent/JP2022062219A/ja not_active Withdrawn
-
2024
- 2024-04-15 JP JP2024065419A patent/JP2024099612A/ja active Pending
-
2025
- 2025-01-16 US US19/023,772 patent/US20250228960A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513068A5 (cg-RX-API-DMAC7.html) | ||
| US20250228960A1 (en) | Methods for increasing efficacy of folr1 cancer therapy | |
| JP2015514716A5 (cg-RX-API-DMAC7.html) | ||
| HK40099496A (en) | Methods for increasing efficacy of folr1 cancer therapy | |
| HK40017480A (en) | Methods for increasing efficacy of folr1 cancer therapy | |
| HK40017480B (en) | Methods for increasing efficacy of folr1 cancer therapy | |
| HK1193760B (en) | Methods for increasing efficacy of folr1 cancer therapy | |
| HK1193760A (en) | Methods for increasing efficacy of folr1 cancer therapy |